Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus Chemotherapy in Squamous NSCLC
NCT02279732Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2014
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of ipilimumab in squamous cell carcinoma of the lung (SCCL), sponsored by Bristol Myers Squibb. Started Oct 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02279732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279732.